Recursion Pharmaceuticals, Inc. RXRX

3.74 (0.15) (3.86%) as of 25 Sep
Market cap
$2.1B
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Dec '19 Jan '20 Dec '20 Jan '21 Dec '21 Jan '22 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
111.54 111.54 111.54 111.54 283.62 298.52 33.26 46.02 31.50 24.51
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/Operating CF
(23.44) (23.44) (23.44) (23.44) (47.21) (49.69) (29.62) (27.69) (16.06) (39.72)
P/B ratio
0.00 0.00 0.00 0.00 5.32 5.60 2.73 4.43 1.79 1.62
Price to Tangible BV
0.00 0.00 0.00 0.00 5.34 5.62 2.74 5.47 3.37 2.78
EV/Sales
79.24 79.24 79.24 79.24 232.78 247.68 19.44 37.19 21.67 14.62
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(8.78) (8.78) (8.78) (8.78) (14.94) (15.90) (9.27) (5.76) (3.55) (2.94)
EV/FCF
(6.18) (6.18) (6.18) (6.18) (11.94) (12.71) (6.41) (5.52) (3.39) (2.87)
Quick Ratio
11.27 11.57 11.44 11.30 11.30 5.52 5.52 4.27 3.45 5.23
Current Ratio
11.43 11.67 11.53 11.46 11.46 5.68 5.68 4.70 3.81 5.50
Net Debt/EBITDA
1.05 3.16 3.13 2.93 2.97 2.24 2.35 1.21 1.31 1.31
Debt/Assets
12.24% 4.73% 3.82% 1.63% 0.10% 6.41% 0.08% 0.17% 1.31% 0.65%
Debt/Equity
0.16 0.06 0.05 0.02 0.00 0.09 0.00 0.00 0.02 0.01
Asset Turnover
0.02 0.02 0.01 0.02 0.02 0.06 0.06 0.07 0.06 0.05
Operating CF/Net income
0.92 0.52 0.52 0.85 0.85 0.35 0.35 0.88 0.77 0.58
Capex/Depreciation
(1.57) 0.00 (1.71) 0.00 (4.73) 0.00 (3.18) (0.51) (0.47) (0.10)
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
49.80% 52.64% 42.18% (110.79%) (34.35%) (46.56%) (49.29%) (69.12%) (61.89%) (59.54%)
ROA
(61.01%) (43.50%) (29.14%) (41.03%) (30.55%) (36.52%) (34.15%) (48.42%) (44.11%) (44.12%)
ROIC
(276.95%) 0.00% 0.00% 0.00% (448.73%) 0.00% 0.00% (313.71%) (65.59%) (103.19%)
Return on Tangible Assets
(65.77%) (31.95%) (32.31%) (33.73%) (33.73%) (40.52%) (42.94%) (76.03%) (69.42%) (83.84%)
Average Days of Receivables
23.77 14.37 14.37 325.98 325.98 25.22 25.22 25.34 304.99 120.47
Research and Development Expense of Revenue
1,975.38% 1,598.16% 1,598.16% 1,326.07% 1,329.05% 389.82% 390.77% 541.17% 534.38% 636.40%
Selling, General and Administrative Expense of Revenue
817.21% 525.39% 637.51% 480.27% 566.73% 204.80% 204.80% 248.62% 302.83% 236.46%
Intangible Assets out of Total Assets
0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.14 0.33 0.32
Share Based Compensation of Revenue
59.72% 0.00% 108.33% 0.00% 145.82% 0.00% 70.05% 120.03% 138.83% 148.93%
Graham Net Nets
0.23 0.23 0.23 0.23 0.16 0.15 0.27 0.12 0.16 0.26
Graham Number
0.00 0.00 29.18 31.91 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(14.29%) (14.29%) (14.29%) (14.29%) (12.85%) (12.21%) (18.15%) (15.70%) (24.56%) (36.19%)
Free Cash Flow Yield
(11.50%) (11.50%) (11.50%) (11.50%) (6.87%) (6.53%) (9.12%) (14.64%) (20.30%) (20.79%)
Revenue per Share
0.11 0.02 0.18 0.06 0.08 0.23 0.23 0.21 0.21 0.17
Operating CF per Share
(2.64) (0.27) (2.08) (0.93) (1.27) (0.48) (0.48) (1.38) (1.31) (0.83)
Capex per Share
(0.18) 0.00 (0.31) 0.00 (0.32) 0.00 (0.21) (0.06) (0.06) (0.02)
Free Cash Flow per Share
(2.83) (0.27) (2.39) (0.93) (1.58) (0.48) (0.69) (1.44) (1.37) (0.85)
Cash per Share
3.48 1.61 12.13 3.04 4.13 3.14 3.14 1.90 2.18 1.67
Shareholders Equity per Share
3.56 1.46 11.11 3.19 4.33 2.77 2.77 2.23 3.77 2.53
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
3.56 1.46 11.11 3.19 4.33 2.77 2.77 2.23 3.77 2.53
Free Cash Flow
(60.95) (45.40) (52.13) (158.61) (198.41) (83.52) (120.88) (300.33) (376.22) (380.43)
Working Capital
69.71 246.38 243.34 488.06 488.06 469.55 469.55 344.97 526.80 665.14
Capital Expenditures
(3.91) (6.73) (6.73) (39.80) (39.80) (37.36) (37.36) (12.55) (17.04) (8.63)
Net Current Asset Value
51.81 212.92 209.88 467.31 467.31 354.33 354.33 247.87 300.45 469.58
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
1.69 0.00 1.70 0.00 3.91 0.00 0.94 0.28 0.29 0.12
Net Profit Margin
(2,668.35%) (2,196.01%) (2,196.01%) (1,832.18%) (1,832.18%) (601.05%) (601.05%) (735.99%) (788.02%) (863.35%)
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.10 0.17 0.15 0.13 0.13 0.16 0.13 0.28 0.26 0.81
Cash ROIC
(49.51%) (13.64%) (13.79%) (20.85%) (21.04%) (18.94%) (16.55%) (43.56%) (30.30%) (25.19%)
Accounts Receivable Turnover
15.36 25.81 25.40 2.20 1.12 6.73 14.47 15.25 2.25 2.02
Accounts Payable Turnover
0.00 0.00 0.00 4.68 0.00 13.14 10.53 9.97 3.54 3.57
Inventory Turnover
— — — 0.00 — 0.00 0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 113.02 0.00 34.40 34.67 33.88 174.38 93.20
Days of Inventory on Hand
— — — 0.00 — 0.00 0.00 0.00 0.00 0.00
Average Receivables
0.15 0.15 0.16 4.62 9.09 5.92 2.75 2.92 26.13 36.91
Average Payables
1.26 1.17 1.07 1.95 2.82 3.70 4.59 4.27 12.78 19.87
Average Assets
101.43 200.01 298.59 454.47 610.35 655.82 701.29 677.49 1,051.15 1,461.36
Average Common Equity
(124.26) (165.28) (206.29) 168.32 542.94 514.37 485.81 474.62 749.11 1,082.82

Fold the line items

Columns are period end dates